Silymarin and its active component silibinin act as novel therapeutic alternatives for salivary gland cancer by targeting the ERK1/2-Bim signaling cascade
- 266 Downloads
Approximately 20% of all salivary gland cancer patients who are treated with current treatment modalities will ultimately develop metastases. Its most common form, mucoepidermoid carcinoma (MEC) is a highly aggressive tumor with an overall 5-year survival rate of ~30%. Until now, several chemotherapeutic drugs have been tested for the treatment of salivary gland tumors, but the results have been disappointing and the drugs often cause unwanted side effects. Therefore, several recent studies have focused on the potential of alternative and/or complementary therapeutic options, including the use of silymarin.
The effects of silymarin and its active component silibinin on salivary gland cancer-derived MC3 and HN22 cells and their underlying molecular mechanisms were examined using trypan blue exclusion, 4′-6-diamidino-2-phenylindole (DAPI) staining, Live/Dead, Annexin V/PI staining, mitochondrial membrane potential (ΔΨm) measurement, quantitative RT-PCR, soft agar colony formation and Western blotting analyses.
We found that silymarin and silibinin dramatically increased the expression of the pro-apoptotic protein Bim in a concentration- and time-dependent manner and, concomitantly, induced apoptosis in MC3 and HN22 cells. We also found that ERK1/2 signaling inhibition successfully sensitized these cells to the apoptotic effects of silymarin and silibinin, which indicates that the ERK1/2 signaling pathway may act as an upstream regulator that modulates the silymarin/silibinin-induced Bim signaling pathway.
Taken together, we conclude that ERK1/2 signaling pathway inhibition by silymarin and silibinin increases the expression of the pro-apoptotic Bcl-2 family member Bim which, subsequently, induces mitochondria-mediated apoptosis in salivary gland cancer-derived cells.
KeywordsSilymarin Silibinin Salivary gland tumor Apoptosis ERK/Bim signaling
This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2014R1A1A2055874 and 2016R1A2B4006794).
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
- 2.S. Schwarz, C. Stiegler, M. Muller, T. Ettl, G. Brockhoff, J. Zenk, A. Agaimy, Salivary gland mucoepidermoid carcinoma is a clinically, morphologically and genetically heterogeneous entity: a clinicopathological study of 40 cases with emphasis on grading, histological variants and presence of the t(11;19) translocation. Histopathology 58, 557–570 (2011)CrossRefPubMedGoogle Scholar
- 6.L. Agoni, I. Basu, S. Gupta, A. Alfieri, A. Gambino, G.L. Goldberg, E.P. Reddy, C. Guha, Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys. 88, 1180–1187 (2014)CrossRefPubMedPubMedCentralGoogle Scholar
- 11.F.H. Schroder, M.J. Roobol, E.R. Boeve, R. de Mutsert, S.D. Zuijdgeest-van Leeuwen, I. Kersten, M.F. Wildhagen and A. van Helvoort, Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur. Urol. 48, 922–930; discussion 930–921 (2005)Google Scholar
- 12.G. Scambia, R. De Vincenzo, F.O. Ranelletti, P.B. Panici, G. Ferrandina, G. D'Agostino, A. Fattorossi, E. Bombardelli, S. Mancuso, Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin. Eur. J. Cancer 32A, 877–882 (1996)CrossRefPubMedGoogle Scholar
- 13.X. Zi, D.K. Feyes, R. Agarwal, Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin. Cancer Res. 4, 1055–1064 (1998)PubMedGoogle Scholar
- 15.G. Deep, R. Agarwal, Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr. Cancer Ther. 6, 130–145 (2007)Google Scholar
- 16.A. Tyagi, K. Raina, R.P. Singh, M. Gu, C. Agarwal, G. Harrison, L.M. Glode, R. Agarwal, Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Mol. Cancer Ther. 6, 3248–3255 (2007)CrossRefPubMedGoogle Scholar
- 22.J.F. Ohren, H. Chen, A. Pavlovsky, C. Whitehead, E. Zhang, P. Kuffa, C. Yan, P. McConnell, C. Spessard, C. Banotai, W.T. Mueller, A. Delaney, C. Omer, J. Sebolt-Leopold, D.T. Dudley, I.K. Leung, C. Flamme, J. Warmus, M. Kaufman, S. Barrett, H. Tecle, C.A. Hasemann, Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11, 1192–1197 (2004)CrossRefPubMedGoogle Scholar
- 23.J.A. Wickenden, H. Jin, M. Johnson, A.S. Gillings, C. Newson, M. Austin, S.D. Chell, K. Balmanno, C.A. Pritchard, S.J. Cook, Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. Oncogene 27, 7150–7161 (2008)CrossRefPubMedPubMedCentralGoogle Scholar
- 33.N. Cidlinsky, G. Dogliotti, T. Pukrop, R. Jung, F. Weber, M.P. Krahn, Inactivation of the LKB1-AMPK signaling pathway does not contribute to salivary gland tumor development - a short report. Cell. Oncol. 39, 389–396 (2016)Google Scholar
- 34.K. Ho, H. Lin, D.K. Ann, P.G. Chu, Y. Yen, An overview of the rare parotid gland cancer. Head Neck Oncol. 3, 40 (2011)Google Scholar
- 39.J. Post-White, E.J. Ladas, K.M. Kelly, Advances in the use of milk thistle (Silybum marianum). Integr. Cancer Ther. 6, 104–109 (2007)Google Scholar
- 40.C. Hoh, D. Boocock, T. Marczylo, R. Singh, D.P. Berry, A.R. Dennison, D. Hemingway, A. Miller, K. West, S. Euden, G. Garcea, P.B. Farmer, W.P. Steward, A.J. Gescher, Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin. Cancer Res. 12, 2944–2950 (2006)CrossRefPubMedGoogle Scholar
- 43.A. Tyagi, R.P. Singh, C. Agarwal, R. Agarwal, Silibinin activates p53-caspase 2 pathway and causes caspase-mediated cleavage of Cip1/p21 in apoptosis induction in bladder transitional-cell papilloma RT4 cells: evidence for a regulatory loop between p53 and caspase 2. Carcinogenesis 27, 2269–2280 (2006)CrossRefPubMedGoogle Scholar
- 48.R. Ley, K. Balmanno, K. Hadfield, C. Weston, S.J. Cook, Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein Bim. J. Biol. Chem. 278, 18811–18816 (2003)Google Scholar
- 52.R.P. Singh, S. Dhanalakshmi, S. Mohan, C. Agarwal, R. Agarwal, Silibinin inhibits UVB- and epidermal growth factor-induced mitogenic and cell survival signaling involving activator protein-1 and nuclear factor-kappaB in mouse epidermal JB6 cells. Mol. Cancer Ther. 5, 1145–1153 (2006)CrossRefPubMedGoogle Scholar